Gregory Reyes is Senior VP & Research at Cyclacel Pharmaceuticals, Inc. (CYCC). They have made 1 open-market trade across 1 company since 2008, most recently 2008-03-20.
CIK 0001404055
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $9K since 2008, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CYCC | 3,000 | $19K |
Shares reported on the most recent Form 4, priced at the 2008-03-21 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CYCC | BUY | 2008-03-20 | 2008-03-21 | $2.90 | $9K | -30.8% | -8.9% | -8.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.